This clinical trial is focused on studying the treatment of retinoblastoma, a type of eye cancer that primarily affects young children. The study aims to evaluate the effectiveness of different treatment strategies to preserve vision and control the disease. The treatments being studied include a combination of medications such as Topotecan, Melphalan, Vincristine Sulfate, Etoposide, Carboplatin, and Melphalan Hydrochloride. These medications are administered in various forms, including solutions for infusion and injection, to determine the best approach for managing retinoblastoma.
The purpose of the study is to assess how well these treatments work in controlling the disease and preserving vision. The study is divided into two parts. The first part focuses on the use of intra-arterial chemotherapy (IAC), which involves delivering chemotherapy directly to the eye, to see how well it controls the disease. The second part evaluates the visual function of patients who receive other conservative treatments, such as intravenous (IV) chemotherapy combined with local eye treatments or local treatments alone, which are less invasive.
Participants in the study will receive one of the treatment options and will be monitored over time to see how well the treatments work in preserving the eye and vision. The study will also look at the visual outcomes based on criteria set by the World Health Organization (WHO). The goal is to find the most effective treatment strategy for children with retinoblastoma, ensuring the best possible visual outcomes while controlling the disease.
France